Murine schistosomiasis mansoni: process of blood coagulation at pre-patent, acute and chronic phases, and consequence of chemotherapeutic cure on the reversion of changes.
The present study aims to elucidate in a sequential manner the changes of the blood coagulation process at different phases of experimental schistosomiasis, comprising the pre-patent, acute, intermediate and chronic phases, and the effect of chemotherapeutic cure, at the acute and chronic phases, on reversion of changes related to the coagulation factors. Mice were infected with Schistosoma mansoni cercariae, and were divided into four groups. Blood samples from these groups were collected 32, 70, 100, and 140 days after infection, corresponding to the pre-patent, acute, intermediate and chronic phases, respectively. Simultaneously, other infected groups were given oxamniquine, 70 and 140 days after infection. At the same time as blood collection from infected and/or treated animal groups, other uninfected control animal groups were punctured and maintained under the same conditions as the infected animals. The vitamin-K-dependent clotting factors were found to be more sensitive to infection at different phases, while factors VIII and XI presented hyperactivity. Results obtained 90 days after chemotherapeutic treatment with oxamniquine, administered at the acute and chronic phases, presented noticeable reversion of the main alterations in the coagulation mechanism. The present study provides unquestionable data on the development of hemostatic changes throughout the course of S. mansoni infection.
Carvalho
Maria G
MG
Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Brazil. mgcarvalho@farmacia.ufmg.br
Mello
Rômulo T
RT
Soares
Anna L
AL
Bicalho
Rosilene S
RS
Lima e Silva
Francisco C
FC
Coelho
Paulo M Z
PM
D000208:Acute Disease; D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D001779:Blood Coagulation Factors / Q000378:metabolism; D002908:Chronic Disease; D005260:Female; D051379:Mice; D010073:Oxamniquine / Q000627:therapeutic use*; D012550:Schistosoma mansoni; D012555:Schistosomiasis mansoni / Q000097:blood* / Q000188:drug therapy* / Q000469:parasitology; D012556:Schistosomicides / Q000627:therapeutic use*
D001779:Blood Coagulation Factors; D012556:Schistosomicides; D010073:Oxamniquine